Tech Company Financing Transactions
Syndax Pharmaceuticals Funding Round
Syndax Pharmaceuticals secured a $26.6 million Series B venture capital round on 8/27/2013. Backers included Domain Associates, Forward Ventures and MPM Capital.
Transaction Overview
Company Name
Announced On
8/27/2013
Transaction Type
Venture Equity
Amount
$26,600,000
Round
Series B
Investors
Proceeds Purpose
Syndax plans to use the proceeds to continue advancement of its late-stage pipeline of epigenetic-based combination therapies for treatment-resistant cancers, including activities in preparation for an NDA-enabling Phase 3 study of entinostat in metastatic breast cancer.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
400 Totten Pond Road 110
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Briggs Morrison
Chief Financial Officer
Allan Shaw
Chief Technical Officer
Peter Ordentlich
President
Michael Metzger
VP - Operations
Jeannette Hasapidis
Browse more venture capital transactions:
Prev: 8/27/2013: Doggyloot Holdings venture capital transaction
Next: 8/28/2013: Speakaboos venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs